BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37147963)

  • 1. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
    Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma.
    Naik M; Rao BV; Fonseca D; Murthy SS; Giridhar A; Sharma R; Raju K; Rao TS; Challa S
    Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):72-78. PubMed ID: 33994731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
    Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
    Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of GATA-3 in urothelial carcinoma variants.
    Liang Y; Heitzman J; Kamat AM; Dinney CP; Czerniak B; Guo CC
    Hum Pathol; 2014 Jul; 45(7):1466-72. PubMed ID: 24745616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
    Mhawech P; Uchida T; Pelte MF
    Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas.
    Garudadri G; Rao BV; Sundaram C; Fonseca D; Murthy SS; Sharma R; Rao TS
    Indian J Pathol Microbiol; 2020 Feb; 63(Supplement):S18-S24. PubMed ID: 32108621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
    Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
    Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
    Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry in diagnostic surgical pathology of the prostate.
    Hameed O; Humphrey PA
    Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
    Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
    J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
    Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
    Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
    Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
    Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
    Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
    Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
    Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review.
    Sanguedolce F; Russo D; Mancini V; Selvaggio O; Calò B; Carrieri G; Cormio L
    Int J Surg Pathol; 2019 Apr; 27(2):120-133. PubMed ID: 30509113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
    Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
    Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
    Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
    Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.